OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Outlook Therapeutics, Inc.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026
$0.49+0.00 (+0.98%)
Close on Oct 19, 2026
- Market cap
- $67.41M
- P/E (TTM)
- –
- Dividend yield
- –
Outlook Therapeutics, Inc. revenue by segment
By business segment
By product or service
By region
From the segment and revenue-disaggregation notes of Outlook Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.